Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Area of Science:

• Urology
• Molecular Biology
• Oncology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men, characterized by nonmalignant prostate enlargement.
• The molecular underpinnings of BPH are not well understood, limiting current therapeutic strategies.
• Existing treatments for BPH have limitations, necessitating novel approaches.

Purpose of the Study:

• To conduct a comprehensive molecular investigation of Benign Prostatic Hyperplasia (BPH).
• To identify distinct molecular subgroups within BPH.
• To explore potential subtype-specific therapeutic strategies for BPH.

Main Methods:

• Genomic, transcriptomic, and epigenetic profiling were utilized for a detailed molecular analysis of BPH.
• Integration of transcriptional and methylation data to identify patient subgroups.
• Validation of identified subgroups in independent patient cohorts.

Main Results:

• Benign prostatic hyperplasia (BPH) showed no evidence of neoplastic features, including low mutation rates and minimal copy number alterations.
• Global hypermethylation was identified as a dominant epigenetic process in BPH.
• Two distinct BPH molecular subgroups with differing clinical features and signaling pathways were identified and validated.
• mTOR inhibitors demonstrated a potential as a subtype-specific therapeutic option, showing prostate size reduction.

Conclusions:

• Benign prostatic hyperplasia (BPH) is characterized by distinct molecular subgroups rather than a single entity.
• The identified molecular subgroups offer opportunities for developing precision therapies.
• Targeting specific BPH subtypes, potentially with mTOR inhibitors, represents a promising therapeutic direction.